Price: $18,900
(including doctor consultation fee)
Lucence INSIGHT™ is an early screening test for multiple cancers based on proprietary amplicon technology. By detecting circulating tumor DNA (ctDNA) and pathogen signals in the blood, 50 high-incidence and high-risk cancers, including lung cancer, breast cancer, colorectal cancer, etc., can be detected simultaneously with a single blood draw.
The proprietary amplicon technology of Lucence INSIGHT™ has excellent cancer screening performance, high sensitivity, and specificity of up to 99%. This test detects early cancer signals by analyzing genomic data extracted from the blood, effectively reducing the sequencing error rate, and accurately identifies the intensity of the positioning signal to predict the origin of cancer, with an accuracy of 88% in tumor tracing.
